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Summary 
The Norwegian Scientific Commitee for Food Safety (VKM) has appointed a working group 
of experts to answer a request from the Norwegian Food Safety Authority regarding risk 
assessment of Lactobacillus fermentum CECT5716 in infant formula intended for use from 
birth (0 month) and in infant formulae and follow-on formulae intended for children after the 
age of 6 month. 
The mandate of this risk assessment was not to evaluate the health claims related to the 
products as such health claims are assessed by EFSA. However, in the EFSA opinions so far 
(November 2009), a cause and effect relationship has not been established between the 
consumption of L. fermentum CECT5716 containing products and the claimed effects. 
In the assessment of L. fermentum CECT5716 by the expert committee in EFSA, the panel 
considered that the strain is sufficiently characterized. 
We are not aware of any data indicating that this strain has been the cause of human disease. 
Its potential toxicity and ability to translocate has been studied in adult mice after oral 
administration of doses 10 000 times greater than those normally consumed by humans 
without observing any bacteremia or translocation to spleen or liver. However, strains of 
Lactobacillus have from time to time been isolated from human blood cultures and may 
therefore, although seldom, translocate. 
L. fermentum CECT5716 is fully susceptible to all antibiotics that are recommended by the 
Panel on additive and products or substances used in animal feed (FEEDAP) of EFSA and is 
considered safe with respect to absence of antimicrobial resistance genes. DNA-sequence data 
do not imply the presence of any gene(s) coding for toxin production, but confirming in vitro-
studies are missing. 
The FBO refers to two randomized clinical studies in healthy infants of 1-6months of age 
with respect to possible safety aspects, concluding that the L. fermentum CECT5716 was well 
tolerated and safe for the groups examined. However, data concerning safety aspects 
specifically concerned with new-borns, or for immunocompromised infants are lacking. The 
FBO has submitted some data regarding possible long-term adverse effects of giving the 
strain daily as a “monoculture” over a prolonged period of time. These data are not sufficient 
to draw any conclusion regarding long-term safety of the strain.   
It is supposed that the early composition of the human gastro-intestinal tract microbiota can 
have long-lasting functional effects. If that is the case, a daily supply of a “monoculture” of a 
single, specific strain such as L. fermentum CECT 5716, in large quantities over a prolonged 
period of time to age groups where the intestinal flora is still developing may therefore have 
unknown, but possible long-lasting adverse effects. 
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Sammendrag 
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag fra Mattilsynet etablert en 
ekspertgruppe for å utarbeide en risikovurdering ved bruk av Lactobacillus fermentum CECT 
5716 som probiotikum i henholdsvis morsmelkerstatning beregnet for nyfødte (0 måneder) og 
i tilskuddsblanding beregnet for barn fra 6 måneders alderen. 
Det har ikke vært vurderingens mandat å evaluere eventuelle helsepåstander relatert til 
produktene da slike påstander vurderes av EFSA. EFSA har imidlertid så langt (november 
2009) konkludert med at det ikke er etablert en årsakssammenheng mellom bruk av produkter 
som inneholder L. fermentum CECT5716 og påståtte helseeffekter. 
I en tilsvarende vurdering av et ekspertpanel i EFSA konkluderes det med at stammen L. 
fermentum CECT5716 er tilstrekkelig karakterisert.   
VKMs ekspertpanel har ikke funnet data som indikerer at stammen har gitt opphav til 
infeksjoner hos menneske. Stammens potensielle toksisitet og evne til translokalisasjon har 
vært undersøkt i dyreforsøk ved bruk av voksne mus og med doser 10.000 ganger høyere enn 
normalt konsumert av mennesker – uten å påvise bakteriemi eller translokering til milt eller 
lever. Likevel – enkelte stammer av Lactobacillus har fra tid til annen blitt isolert fra humane 
blodkulturer og kan derfor, om enn sjelden, translokere. 
L. fermentum CECT5716 er fullt følsom for alle antibiotika som anbefales av EFSAs «Panel 
on additive and products or substances used in animal feed (FEEDAP) og kan anses trygg når 
det gjelder fravær av antibiotika resistensgener. DNA-sekvensdata indikerer at det ikke 
foreligger gener som koder for toksinproduksjon, men bekreftende in-vitro-studier mangler. 
Når det gjelder mulige bivirkninger på kort sikt, henviser produsenten til to relativt små 
randomiserte kliniske studier hos friske barn i aldersgruppen 1-6 måneder som konkluderer 
med at L. fermentum CECT5716 ble godt tolerert og var trygg for de undersøkte gruppene. 
Imidlertid mangler tilsvarende data for nyfødte (fra 0 måneder) og for grupper av ikke-friske 
barn (f. eks. immunkompromitterte). Når det gjelder eventuelle bieffekter på lang sikt, 
henviser produsenten til et abstrakt av en foreløpig ikke publisert rapport hvor barna i den ene 
av de ovennevnte studiene er fulgt til 3 årsalderen og hvor den foreløpige konklusjonen er at 
det ikke er påvist signifikante antropomorfiske eller helseforskjeller etter 3 år. Men 
utgangspunktet har altså vært friske barn som fikk probiotika fra 1 måneders alderen. 
Dokumentasjonen av sikkerheten for alle grupper av nyfødte (friske og ikke-friske fra 0 
måneders alderen) anses derfor for ikke å være adekvat og data fra eldre barn kan ikke 
ekstrapoleres til denne aldersgruppen. 
Det er antatt at den tidligste sammensetningen av den mikrobielle gastro-intestinale floraen 
kan ha langvarige funksjonelle effekter. Hvis det er tilfelle, kan en daglig tilførsel av en 
tilnærmet «monokultur» i store mengder av en spesifikk stamme (som L. fermentum 
CECT5716) over en lengre periode til de aldersgruppene hvor den intestinale floraen er i ferd 
med å etableres, tenkes å ha langvarige, om enn foreløpig ukjente, bieffekter. 
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Background 
The Norwegian Scientific Committee for Food Safety (VKM) has published several risk- and 
benefit assessments concerning probiotics in products intended for infants and young 
children. 
The Norwegian Food Safety Authority (NFSA) has, based on these assessments by the VKM, 
prohibited the sale of a follow-on formula containing probiotics and certain processed cereal-
based foods for infants and young children containing probiotics. 
The NFSA has received a request from a food business operator (FBO) for an evaluation of 
two products containing probiotics which they are planning to introduce on the Norwegian 
market, - an infant formula and a follow-on formula, both supplemented with Lactobacillus 
fermentum CECT5716. The NFSA sent a request (draft sent in December 2012) to the VKM 
to assess the safety and suitability of the bacterial strain. The assessment should be based on 
the latest scientific documentation submitted by the FBO. The FBO has provided 
documentation concerning the bacterial strain, including evidence of the probiotic effect, in 
addition to documentation on the safety and suitability of the bacterial strain for infants.  
The formal request for the assessment of the bacterial strain and the use for infants was sent 
from the NFSA to the VKM in December 2013. This assessment is requested in order to 
evaluate whether the requirements of safety and suitability given in the legislation for infant 
formulae and follow-on formulae and in the legislation for foods for particular nutritional 
needs are fulfilled.  
 
Terms of reference 
Translated from Norwegian terms of reference: 
The Norwegian Food Safety Authority has requested the VKM to answer the questions in two 
steps: 
 
Step 1 
1) Lactobacillus fermentum CECT5716 in infant formulae: 
a) can Lactobacillus fermentum CECT5716 safely be given to infants (from birth)? 
b) are there any contraindications concerning the use of infant formulae supplemented 
with Lactobacillus fermentum CECT5716 (from birth)? 
 
2) Lactobacillus fermentum CECT5716 in follow-on formulae: 
a) can Lactobacillus fermentum CECT5716 safely be given to infants (from 6 months 
age)? 
b) are there any contraindications concerning the use of follow-on formulae 
supplemented with Lactobacillus fermentum CECT5716 to infants (from 6 months 
age)? 
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Step 2 
The term suitability should be evaluated in light of the documentation submitted by the FBO 
 
1) Are infant formulae supplemented with Lactobacillus fermentum CECT5716 suitable for 
infants (from birth)? 
2) Are follow-on formulae supplemented with Lactobacillus fermentum CECT5716 suitable 
for infants (from 6 months age)? 
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Literature 
Data sources are articles and reports submitted by the FBO.  
The following reports and articles have been provided by the FBO: 
 Safety and Efficacy of L. fermentum CECT5716: Answer to Questions from VKM 
 L. fermentum CECT5716 Hipp Infant milk Formula dossier  
 Maldonado J, Canabate F, Sempere L, Vela F, Sanchez AR, Narbona E, et al. Human 
Milk Probiotic Lactobacillus fermentum CECT5716 Reduces the Incidence of 
Gastrointestinal and Upper Respiratory Tract Infections in Infants. J Pediatr Gastroenterol 
Nutr. 2012; 54(1): 55-61. 
 Gil-Campos M LM, Rodriguez-Benitez V, Romera J, Roncero I, Linares D, Maldonado J, 
et al. Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1 to 6 
months of age: a randomized controlled trial.  Pharmacol Res. 2012 Feb;65(2):231-8 
 
Other relevant background papers used in this assessment are previous opinions on probiotics 
from VKM: 
 The use of probiotics for patients in hospitals. A benefit and risk assessment (Halvorsen et 
al., 2009). 
 Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant 
formula and baby foods (II). VKM 2007.  
 Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant 
formula and baby foods. VKM 2005. 
 Assessment of benefits and risks of probiotics in processed cereal-based baby foods 
Bifidobacterium lactis Bb12. VKM 2010. 
 Nytte- risikovurdering av probiotika i barnemat med fokus på bakterien Lactobacillus 
paracasei ssp. paracasei F19 
 
In addition, the following two literature searches were performed in the PUBMED: 
1. ("lactobacillus fermentum"[MeSH Terms] OR ("lactobacillus"[All Fields] AND 
"fermentum"[All Fields]) OR "lactobacillus fermentum"[All Fields]) AND 
CECT5716[All Fields] 
The search returned 10 results. 
Relevance screening 
The titles of all hits were scanned, and for those that were of potential relevance, the abstracts 
were also inspected. The relevance screening was performed by the members of the ad hoc 
group, independently. Citations were excluded if they did not relate to the terms of reference. 
The reference lists in selected citations were scrutinized to identify additional articles or 
reports, overlooked by the PubMed searches. 
 
2. ("probiotics "[MeSH Terms] AND "gut microbiota "[All Fields]) AND infants [All 
Fields] 
The search returned 114 articles. 
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Relevance screening 
The titles of all hits were scanned, and for those that were of potential relevance, the abstracts 
were also inspected. The relevance screening was performed by the members of the ad hoc 
group, independently. Citations were excluded if they did not relate to the terms of reference. 
The reference lists in selected citations were scrutinized to identify additional articles or 
reports, overlooked by the PubMed searches. 
 
Introduction 
There are currently no regulatory guidelines for use of probiotic food in Norway. The strain 
identification and characterization and safety aspects of Lactobacillus fermentum CECT5716 
have been evaluated, based on the recommendation from “Guideline for use of probiotics in 
food” (FAO/WHO 2002) and our previously risk/benefit assessments listed under Section 
Literature. 
In this assessment we have defined newborns as children less than 1 month and infants as 
children between 1 and 12 months. 
This assessment is based on the evaluation of the documentation listed above, under section 
Literature. The submitted data provided by the FBO give information regarding the probiotic 
strain, safety and efficacy of their products. 
The provided data have been used to evaluate the safety aspects of the probiotic strain L. 
fermentum CECT5716 added to infant formulae and supplements. 
It is not in the mandate of this report to evaluate the health claims related to the products as 
these are assessed by European Food Safety Authority (EFSA). The health claims for L. 
fermentum CECT5716 were evaluated by the EFSA (2010). Notably, the FBO has provided 
one new randomized clinical trial (Gil-Campos et al. 2012) which was not evaluated by 
EFSA. The safety aspects of this trial have been evaluated and commented in this current 
assessment. 
Functions of intestinal microbiota of the newborn and infants 
The role of human intestinal microbiota during early life stages has been redefined during 
recent years. It is today considered as being much more important than earlier understood 
(Collado et al. 2012) and it is now known to have a critical role in the evolution of the 
intestinal functions and in the overall health-status of the host. The development of the 
intestinal microflora occurs primarily during infancy, and a distortion in any of the functions 
of the microbiota could potentially contribute to a wide range of diseases in later life 
(Vael&Desager 2009).  
A normal human intestinal microbiota after the newborn-age is a complex system consisting 
of a dynamic population of around 500-1000 different microbial species, mainly of bacteria. It 
is assumed that a fraction (about 25%) of these species is still unknown, and thus not 
identified. Each individual is estimated to carry at least 160 species at any time (Collado et al. 
2012), inhabiting a diversity of environmental niches through the gastrointestinal tract.  
The gut microbiota constitutes a critical stimulus for the adequate development and 
maturation of the immune system, which contributes to reducing infections and aberrant 
immune response. Exposure to microbes in early life, which largely occurs through the 
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microbial colonization of the intestine of the newborn, has been related to an enhancement of 
gut barrier function and stimulation of immune development. Intestinal colonization is a 
substantial antigenic challenge for the newborn and is essential for the maturation of the gut-
associated lymphoid tissue and for the regulation of the development of intestinal physiology 
(Collado et al. 2012). 
One of the basic physiological functions of the resident microbiota is a microbial barrier 
against microbial pathogens. The mechanisms by which the species of the microbiota exert 
this barrier effect are still largely unknown. There seems to be increasing evidence that 
lactobacilli and bifidobacteria, which are part of the gastrointestinal microbiota, have 
antimicrobial activities that participate in the hosts gastrointestinal system of defense (Servin 
2004, Olivares et al. 2006). 
The development of intestinal microbiota is a complex process. It has traditionally been 
assumed to start at birth when the infant is exposed to the mothers’ microbiota and continues 
to develop and change during life. At birth the neonate is exposed to a great variety of new 
microbes and the infant gut becomes gradually colonized by a rapidly diversifying 
microbiota. The composition of this microbiota depends on several factors, including the 
maternal microbiota, the diet and lifestyle of the mother, the gestational age, mode of 
delivery, the diet of the infant, lifestyle and geographical location, possible use of antibiotics, 
probiotics and prebiotics, or whether the newborn is hospitalized or not. Some publications 
have reported lactic acid bacteria and bifidobacteria in breast milk (Martin et al. 2003, Martin 
et al. 2004). 
The first microbes to colonize the infant gastro-intestinal tract (GIT) are normally facultative 
anaerobes such as enterobacteria, coliforms, lactobacilli and streptococci followed on the 2nd-
3rd day by anaerobes such as bifidobacteria, bacteroides, and clostridia as the main microbes 
in the faeces of 1 to 2-week-old newborns (Collado et al. 2012). Bifidobacteria and 
lactobacilli are Gram-positive lactic acid-producing bacteria which thereafter normally 
constitute a major part of the microflora in the small intestine. 
The microbiota of the infants gut is partly dependent upon the delivery method. Following 
vaginal delivery, bacteria from the maternal vaginal and intestinal microbiota colonize the 
infant, whereas following cesarean section, bacteria from the maternal skin surface and from 
the surrounding environment will colonize the gut of the newborn. Newborns delivered by 
cesarean section will have a deficiency of strict anaerobes with lower numbers of E. coli, 
Bacteroides and bifidobacteria and a higher presence of Clostridium species compared with 
vaginally born infants (Di Mauro et al. 2013).  During the early stages of life, the composition 
of the intestinal microbiota undergoes major modifications, depending on the feeding pattern. 
Breast-fed infants can have an increased number of Bifidobacterium and lactobacilli, whereas 
formula fed infants can have more enterococci and bacteria belonging to the genus 
Enterobacteriaceae (Di Mauro et al. 2013). However one study concludes that “analysis of 
infant fecal samples show that the density and distribution of bacterial species are highly 
variable with no consistent effects of gestational age, delivery mode, diet or probiotic 
administration, while low bacterial diversity and bacterial overgrowth are commonly 
associated with necrotizing enterocolitis” (Cilieborg et al. 2012).  
The initial bacterial colonization after birth, and its change according to environment, nursing, 
weaning and drugs, plays a crucial function in the final development of the gut with large 
shifts in the relative abundances of taxonomic groups. However, the real microbial diversity 
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and the general composition of the infant gut still remain controversial and insufficiently  
studied (Di Mauro et al. 2013). 
It is considered that a balance of the microbial groups present in the human gut is crucial for 
maintaining health. When this balance is disturbed, it is assumed that the host-microbe 
relationship can progress toward a disease state. “Altered intestinal colonization by 
commensal microorganisms … and reduced microbial diversity has been reported in preterm 
infants increasing the risk to develop later disease” (Collado et al. 2012). Such diseases may 
include inflammatory bowel diseases, necrotizing enterocolitis, obesity, various forms of 
colitis and even autism has been linked to disturbances in human-associated microbiotia. 
Numerous studies have linked early gut microbiota to the development of atopic diseases and 
indicated a link between specific bifidobacteria deficiency and increased incidence of atopy. 
However, no specific microbes have been identified with consistently harmful or protective 
roles regarding atopic diseases and conflicting results have been obtained regarding the 
protective role of different Bifidobacterium species (Collado et al. 2012). 
Possible functions of probiotics 
A current level of consensus on probiotic science has been summarized by different 
international expert panels and bodies, with substantial evidence for beneficial effects and 
areas with poor or inconsistent effects (Rowland et al. 2010, Braegger et al. 2011, EFSA 
Panel on Dietetic Products 2014). 
The effects of specific probiotic strains are supposed to be mediated by direct interaction with 
intestinal barrier function or through interactions with immune intestinal cells, especially in 
the upper part of the gut where probiotics may transiently dominate. Other effects may be 
mediated indirectly via modulation of gut microbiota, by changing the gut microenvironment, 
e.g. through bacteriocin production or competitive exclusion. However, “there is a wide range 
of possible mechanisms which are only just beginning to be unraveled and need further 
investigations” (many of these mechanisms possibly cannot easily be measured in humans for 
ethical or feasibility reasons) (Rowland et al. 2010). 
There is a general agreement among experts that possible probiotic effects are species and 
often strain specific. Probiotics can therefore not be properly evaluated as a class but need to 
be judged on single strain basis.  
The intestinal faecal microbiota of the healthy, full-term, vaginally delivered and breast-fed 
infant is regarded as the “gold standard” for a balanced gut microbiota. However, what 
exactly constitutes a balanced gut flora has not been defined. Since the intention of probiotic 
therapy would be to modulate an undefined, but supposedly unbalanced indigenous 
microbiota, the possible effect of deliberately modulating an infant’s gut flora (with probiotic 
bacteria) should probably be of concern.    
In accordance with this, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
concludes in its “Draft Scientific Opinion on the essential composition of infant and follow-
on formula” (2014): “Taking into account the lack of convincing evidence for a benefit of the 
addition of “probiotics” or “synbiotics” to IF (infant formula) and/or FOF (follow-on 
formula), the Panel considers that the addition of “probiotics” and/or “synbiotics” to IF or 
FOF is not necessary”. 
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Influence of probiotics on the infant gut microbiota 
The criteria for selecting articles to evaluate the effects of probiotics on infant’s microbiota 
have been described under Literature search section. Only original studies were included and 
10 studies fulfilled our inclusion criteria. A summary of the studies and an evaluation of each 
study are presented in Appendix I. Data are based on isolation of bacterial species from 
faeces. Due to great variation in methodology used in these studies (conventional culturing, 
molecular methods), and also including which probiotic strains and dose, age of the infants, 
duration of the interventions, delivery of child (vaginal, caesarean), bias caused by different 
lifestyle of studied populations, diversity of the normal flora of individuals, genetic 
differences, age and sex, it is difficult to collate the data. One of the limitations of these 
studies is the use of conventional culturing method. Approximately 60-80% of gut bacteria 
cannot be cultured using conventional culturing methods and molecular methods like analysis 
of 16S rRNA are considered more sensitive for quantitative and qualitative analysis of gut 
microbiota (Panigrahi et al. 2008). This method was not used in all evaluated articles.   
The definition of “normal” infant gut microbiota is difficult and almost impossible. The use of 
probiotics in infants aims to create an intestinal microbiota whose composition is close to that 
of breastfed term infants. The findings presented in the Appendix I cannot confirm this claim 
and data are diverging. In some studies the authors concluded that the infant´s microbiota was 
influenced by probiotics, in other studies not. There is insufficient data in all studies to enable 
an evaluation of the clinical impacts of various composition of infant´s microbiota, whether 
dominated by Lactobacillus/Bifidobacterium, or by Enterobacteriaceae /Clostridium/ 
Bacteriodes/ Enterococcus. We cannot draw any firm conclusion from the data presented in 
Appendix I, which demonstrates great variation in individual level. 
Not all species of Lactobicillus/Bifidobacterium are necessarily correlated to “healthy” gut. 
Recent research indicates that “maternal” Lactobacillus/Bifidobacterium may easily colonize 
the breastfed infants’ gut. Fernandez et al. (2013), proposed that these strains could 
translocate to the mammary gland through an endogenous route involving maternal dendritic 
cells (DCs) and macrophages. The Lactobacillus/Bifidobacterium presented in breast milk 
may also contribute to infant digestion through break down of sugars, proteins and other 
nutrients in breast milk. It can be speculated that these strains are individual-specific based on 
the composition of the breast milk and may not be used as universal. This may be the reason 
why commercial probiotic strains are not able to colonize in infants as they are not recovered 
in faecal samples from children who are been fed with probiotics, after a relatively short time 
following cessation of consumption. 
 
Hazard identification and characterization 
Identification of the bacteria  
Lactobacillus fermentum is a Gram-positive, heterofermentative rod-shaped lactic acid 
bacterium.  
The strain L. fermentum CECT5716 is marketed as L. fermentum heriditum® 
L. fermentum CECT5716 is deposited at the Spanish Type Culture Collection 
(http://www.cect.org/english/). CECT accepts deposits as a restricted-access non-public 
International Depositary Authority under the Budapest Treaty. 
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In the assessment of this strain by the expert committee in EFSA, The Panel considers that the 
food constituent, Lactobacillus fermentum CECT5716, which is the subject of the health 
claims, is sufficiently characterized. 
The aspects discussed below are recommended in the guidelines for probiotics (FAO/WHO 
2002). 
Pathogenic criteria  
Translocation  
The ability of L. fermentum CECT 5716 to translocate from the gut of mice to different 
tissues was studied by Lara-Villoslada et al. (2009). No bacteraemia was observed in any of 
the experimental groups. Liver and spleen were aseptically removed and the presence of 
bacteria was analysed by culture in de Man, Rogosa and Sharpe agar (MRS), a lactic acid 
bacteria elective medium, and brain heart infusion agar (BHI), a less specific medium. 
Although translocation of bacteria to liver and spleen was observed, there was no statistically 
significant difference in the incidence of translocation to liver or spleen between control and 
treated groups. In addition, colonies found on agar plates were checked by conventional PCR 
using specific primers and none of the colonies corresponded to the administered strain L. 
fermentum CECT5716.  
The experimental study provided by the FBO indicates that L. fermentum CECT5716 did not 
translocate in mice. We are not aware of data which may indicate the translocation of L. 
fermentum CECT5716 in humans.  
Platelet aggregation 
Platelet aggregation contributes to the pathogenesis of infectious endocarditis and some 
microorganisms may increase platelet aggregation. So far however, very few studies have 
been found in which probiotic strains were investigated for their platelet aggregation 
properties (Halvorsen et al. 2009). 
The literature search has not found any data on platelet aggregation by L. fermentum 
CECT5716.  
 
Antimicrobial resistance properties of L. fermentum CECT5716  
The FBO has submitted a single study (Lara-Villoslada et al. 2009) regarding the 
antimicrobial susceptibility of L. fermentum CECT5716. Minimum Inhibitory Concentration 
(MICs) of 12 antimicrobial agents was determined by a microdilution method. Nine of the 
antimicrobial agents tested were those for which EFSA has established microbiological 
breakpoints (cut-off values) can be used for distinction between L. fermentum strains 
harbouring acquired antimicrobial resistance and susceptible strains (EFSA 2008). These 
agents included ampicillin, gentamicin, streptomycin, quinpristin/dalfopristin, erythromycin, 
clindamycin, oxytetracycline, chloramphenicol, kanamycin. MICs of three antimicrobial 
agents (Linozolid, penicillin G, and fusidic acid) for which tentative cut-off values for L. 
fermentum have been suggested (Klare et al. 2007) were also determined.   
L. fermentum CECT5716 was showed to be susceptible to all tested antimicrobial agents.  
According to data provided by the FBO, the strain does not harbour plasmid, IS-element(s) 
and transposon(s) associated with antimicrobial resistance gene(s) (Jimenez et al. 2010).   
 Norwegian Scientific Committee for Food Safety (VKM) 13-106-endelig 
 
 
15 
 
 
The sequence data for the L. fermentum CECT 5716 genome are available in GenBank/EMBL 
under accession no. CP002033. In a rapid screening of the sequence data, 54 transposase 
genes and 4 putative transposase genes were identified in the L. fermentum CECT 5716 
genome.  Transposon is a class of genetic elements that can “jump” to different locations 
within a genome, either alone or with other genes like antimicrobial resistance genes. 
Although these elements are frequently called “jumping genes,” they are always maintained 
in an integrated site in the genome. In addition, most transposons eventually become inactive 
and no longer move. 
No antibiotic resistance genes, virulence factors or pathogenic factors were identified in the L. 
fermentum CECT 5716 genome, in association with the transposons or putative transposon 
genes. 
 
Properties of L. fermentum CECT5716 relevant to survival and persistence 
in the gastrointestinal tract and effect on epithelial cells 
Resistance to gastric acidity and bile salts 
Following ingestion, the first major potentially inhibitory or fatal hurdle for bacteria in foods 
is the low pH in the stomach. The pH may be as low as 2 in fasting conditions but higher 
following ingestion of food. In the duodenum, bile salts are excreted into the lumen and can 
also exert an antibacterial effect. Bile salts may be inhibitory or destructive to bacterial cells. 
In vitro testing of tolerance to bile salts is usually carried out by addition of various levels of 
bile salts to a suitable growth medium (Saarela et al. 2005, Vernazza et al. 2006).  
Martin et al. (2005) studied the probiotic potential of several strains, including L. fermentum 
CECT 5716. Survival in a gastrointestinal model, where the bacteria were added in fermented 
milk to a simulated digestion (both low pH and then bile salts), showed 74% survival of cells. 
This indicates that the strain could survive to the small intestine. 
Adherence to cell lines and human epithelial cells 
The ability to adhere to intestinal surfaces is thought to be important for the efficacy of 
probiotic strains, and is claimed to be one of the main criteria for selecting such strains.  
The FBO claims that L. fermentum CECT5716 shows “a high rate of adhesion to intestinal 
cells” (Martin et al. 2005).  
 
Safety aspects  
Regarding safety, the following aspects are of great importance:  
Antibiotic resistance  
The study (Lara-Villoslada et al. 2009), provided by the FBO, showed that L. fermentum 
CECT5716 is susceptible to all tested antimicrobial agents; ampicillin, gentamicin, 
streptomycin, quinpristin/dalfopristin, erythromycin, clindamycin, oxytetracycline, 
chloramphenicol, kanamycin, Linozolid, penicillin G, and fusidic acid. Thus, L. fermentum 
CECT5716 fulfils one of the important criterion regarding safety aspects of probiotic strains. 
The safety aspect of L. fermentum CECT5716 regarding absence of phenotypically antibiotic 
resistance properties and resistance gene(s) is considered acceptable. 
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Occurrence of disease 
We are not aware of any data which can indicate L. fermentum CECT5716 as a cause of 
disease. However, strains of Lactobacillus have been reported to be isolated in blood culture 
from many patients with bacteraemia (Yazdankhah et al. 2009). In a randomized, placebo-
controlled trial, L. rhamnosus strain GG was not shown to be effective in reducing the 
incidence of nosocomial infections. In fact, a statistically nonsignificant trend toward an 
increase in infection was seen (four vs. 11) (Honeycutt et al. 2007). Due to safety concerns 
regarding the administration of L. rhamnosus GG, the study investigators terminated the 
study. 
Mammalian toxin production or hemolytic potential of the probiotic strain 
In answer to the question in our documentation checklist, the FBO claims no toxin production 
or hemolytic potential for L. fermentum CECT5716. In the screening of the sequence data 
(accession no. CP002033), no gene(s) encoding for toxin(s) or hemolysis were identified. 
However, the FBO has not provided any in vitro studies, which may prove the absence of 
toxin production or haemolytic potential for L. fermentum CECT5716. There is probably no 
reason to believe that L. fermentum CECT5716 may produce toxins to mammalian cells or 
has haemolytic activity. 
Possible infectivity of probiotic strain in immunocompromised individuals  
The FBO has not provided any data, which can justify the use of L. fermentum CECT5716 in 
immunocompromised individuals, critically ill patients, postoperative and hospitalized 
patients, neither adults nor children.  No contra-indication has been claimed by the FBO for 
the use of L. fermentum CECT5716 in these patient groups. 
Due to lack of data, the use of L. fermentum CECT5716 in these susceptible groups of 
patients is not considered acceptable.  
Assessment of undesirable short-term side-effects  
The FBO has provided the results from two randomized controlled trials in infants, one 
conducted in the period May 2008-July 2009 (Maldonado et al. 2012) and the other May 
2009-September 2010 (Gil-Campos et al. 2012). These studies, seemingly from the same 
group, are both rather small, including totally 137 and 126 healthy infants of 1-6 months of 
age, following the children for up to 6 months. New-borns were not included. Both studies 
concluded that L. fermentum CECT5716 was well tolerated and safe for the groups examined. 
Data regarding safety aspects for new-borns (0-1 month) or for not-healthy infants (e.g. 
critically ill patients, immunocompromised, postoperative or hospitalized patients, preterm) 
are not presented.  
The data from infants aged 1 to 6 month cannot be extrapolated to infants < 1 month. The 
FBO has applied for marketing authorization for their products for infants from birth (0 
month). Thus the short-term side-effects in this age group are not studied and not known.  
Assessment of undesirable long-term side-effects  
The FBO states that “L. fermentum CECT5716 was isolated from human milk (Martin et al. 
2003) and as such of human origin. The intake of L. fermentum CECT5716, as a natural 
component of human milk, is the best indicator of its long-term safety”. This argument may 
be contested, as one isolate from one human milk-specimen does not necessarily imply that it 
is “a natural component of human milk”.   
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The potential toxicity and ability of the strain to translocate has been tested in mice after oral 
administration of doses 10.000 times higher than those normally consumed by humans (Lara-
Villoslada et al. 2009) without observing any bacteraemia or translocation to spleen or liver.  
There is a lack of adequate data regarding possible long-term effects of giving the strain daily 
as a “monoculture” over a prolonged period of time. The FBO has provided the abstract of a 
hitherto unpublished article where the 126 infants given infant formula supplemented with L. 
fermentum CECT5716 in a previous study (Gil-Campos et al. 2012) were followed for 3 years 
(Maldonado-Lobon et al. 2014). According to the protocol of this follow-up study, provided 
by the FBO, the authors had defined the primary response as the children´s weight and 
growth. The secondary response were defined as; allergies, infections and illness suffered by 
the child, intestinal microbiota of the child, faecal concentration of short chain fatty acids, 
faecal concentration of IgA, parameters relating to children´s intestinal function. The abstract 
provided by the FBO does not give all these data intended to be measured during the follow-
up study. At the age 3 years, anthropometric data of 107 children were collected and related to 
the health of the children. There were no differences in weight values although greater length 
was observed in children of probiotic group according to the difference already observed at 6 
months of age. The authors concluded further that “No significant differences in the incidence 
of metabolic diseases, allergy or infectious diseases were observed” and that the data 
therefore support the long-term safety of consumption of infant formula supplemented with L. 
fermentum CECT5716 during the first months of life.   
The provided data regarding long-term safety is only an abstract and this is therefore not 
sufficient for evaluation. In any case, the study includes only healthy children who have got 
the probiotic-supplemented infant formula only after the age of 1 month. It does therefore not 
include newborns or special groups of not-healthy children. The aspect of long-term safety 
may therefore be regarded as inadequately documented.    
Influence of L. fermentum CECT 5716 on infant gut microbiota  
According to the follow-up study protocol, the authors had planned to identify the long-term 
effect of L. fermentum CECT 5716 on infant´s microbiota, but this has not been provided by 
the FBO. Therefore, this issue cannot be assessed further. The need for data on long-term 
effects is discussed in “Assessment of undesirable long-term side-effects”. 
The data presented on Appendix I, for other probiotic strains cannot be extrapolated to L. 
fermentum CECT 5716, since probiotic effect is strain-specific. 
 
Exposure assessment 
Information supplied by FBO and label on the product show that the infant formula contains 
log 7 cfu g-1 powder. According to the manufacturer’s instructions, for a 2 month infant of 
5kg, 5 scoops (1 scoop = 4.3g powder) of powder should be added to 150g (ml) water. The 
number of viable cells of L. fermentum CECT 5716 in the ready to eat serving would then be 
log 8.33 cfu. With five servings per day, the total number of cells ingested per day would be 
approximately log 9.  
There is a lack of dose-response studies as a basis for supplementation of the amount L. 
fermentum CECT 5716 to infant formula.  
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As a comparison, a 100g serving of commercial probiotic yoghurt would contain 
approximately log 9-10 cfu. 
Studies of the microflora of human breast milk are sparse. Albesharat et al. (2011) reported 
lactic acid bacteria in numbers up to log 3 cfu (assume per mL) in the breast milk of lactating 
Syrian women. Zacarias et al. (2011) reported the presence of bifidobacteria (up to log 2,8 cfu 
mL-1) in 6 of 22 women in Argentina. Solis et al. (2010) isolated Streptococcus, 
Enterococcus, Bifidobacterium and Lactobacillus in numbers as high as log 5 cfu mL-1 in 
breast milk from lactating women in Spain and also found congruity with the infant´s faecal 
flora. Fernandez et al.  (2013), in a review article, extrapolated results of several authors and 
estimated that an infant would consume between log 5 and log 7 bacteria daily along with the 
consumption of 800 ml breast milk. Thus the amount of cells consumed by an infant of L. 
fermentum CECT 5716 according to the manufacturer’s instructions would to be considerably 
higher than natural milk levels, in fact up to 10 000 x greater (difference between log 5 and 
log 9). 
 
Risk characterization 
For characterization of risk related to the consumption of L. fermentum CECT5716, we have 
evaluated the following aspects; antibiotic resistance property, occurrence of disease, 
mammalian toxin production or haemolytic potential of the probiotic strain, possible 
infectivity of probiotic strain in immunocompromised individuals, assessment of undesirable 
side-effects (short-term, and long-term).  
The FBO has provided no data regarding safety aspects for newborns (0- 1 month), since 
newborns were not included in the clinical trials. Due to lack of data for children on this age 
group, the recommendation for use of L. fermentum CECT5716 is not acceptable and data 
from older children cannot be extrapolated to this age group.   
The safety aspect of L. fermentum CECT5716 regarding absence of acquired antibiotic 
resistance and resistance genes is considered acceptable. We are not aware of any data 
indicating that the consumption of this strain has caused human diseases. However, 
Lactobacillus as a genus has, from time to time, been isolated from human blood cultures and 
may therefore, although seldom, translocate. In the screening of the sequence data no gene(s) 
encoding for toxin(s) or haemolysins were identified. Theoretically, toxin production should 
not pose any problem with this strain.  
The FBO has not provided any data to support the safe use of L. fermentum CECT5716 in 
immunocompromised individuals, critically ill patients, postoperative and hospitalized 
patients, neither in adults nor in children. The FBO has not indicated that the L. fermentum 
CECT5716 may be used in these groups of children or whether it is contra-indicated.  The 
potential pathogenicity of Lactobacillus is also listed in (Halvorsen et al. 2011).     
The FBO has not provided any data regarding effect of L. fermentum CECT 5716 on the 
composition of the infant microbiota, although according the protocol of the follow-up study 
provided by the FBO, these data may have been collected.   
The data provided by the applicant show no short-terms side effect in the submitted clinical 
studies, however, the long-term safety data is lacking. A daily supply of a “monoculture” of a 
particular strain in large quantities over a prolonged period of time to an age group lacking an 
established intestinal flora may have unknown adverse effects. The early microbial 
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composition of the human gastro-intestinal tract has long-lasting functional effects. If the 
supply of a “monoculture” leads to an abnormal colonization of the infant gut, the result may 
be that the postnatal immune system development is affected, that the postnatal maturation of 
epithelial cell barrier functions is delayed or it can lead to mucosal inflammation that plays a 
pivotal function in the development of feeding intolerance (Di Mauro et al. 2013).  It is not 
known at what point in life an early change of the GIT microbiota could have a negative 
effect. 
The long-term effects of infant formulas supplemented with probiotic strains have already 
been discussed for other products supplemented with other probiotic strain (Halvorsen et al. 
2011). From birth to 24 months, and especially after weaning, 500-1000 bacterial species are 
normally established in the intestinal tract. This individual intestinal microbiota is 
continuously influencing the host and the host’s immune system, establishing physiological 
functions and defense mechanisms. The immaturity and vulnerability of the intestinal 
microbiota and the immune system makes the two lowest age groups at the highest risk of 
unwanted health effects of the daily intake of probiotics. A daily intake of probiotics may 
have negative effect on establishment of intestinal bacterial flora and development of 
intestinal functions and mucosal immune system in all of the three different age groups. 
Possible long-term effects of a yearlong monocultural supply in these age groups, have to the 
best of our knowledge, not been evaluated by the FBO. Our assessment of exposure shows 
that the amount of cells of L. fermentum CECT 5716 consumed by an infant according to the 
manufacturer’s instructions would to be considerably higher than natural levels possibly 
present in breast milk, in fact up to 10 000 x greater (difference between 105 and 109). 
Due to many uncertainties and lack of knowledge discussed above, the safety of long term use 
of L. fermentum CECT 5716 has not been adequately proved. 
The addition of probiotics in infant formula raises several ethical dilemmas where the risks 
and benefits have to be considered together. For instance, is it acceptable to:  
 Apply a potential health-promoting treatment to premature babies when long term 
negative effects cannot be excluded. 
 Not apply a potential health-promoting treatment due to fear of side effects which may be 
overestimated. 
 Carry out tests on babies, both premature and infants, who have no option to choose 
themselves, when long term side effects cannot be excluded.  
The dilemma is how great a risk can be accepted compared to the potential benefits. In life-
saving treatments, the acceptable risk is relatively high, as the benefit is potentially high. 
However the accepted risk is lower when a product is for normal use. Even clinical testing of 
babies can be questioned which would result in no products of this kind considered safe due 
to lack of evidence. 
 
Data gaps 
 Influence of probiotics on infant gut microbiota 
 The metabolic activity of L. fermentum CECT5716 on nutrients supplemented to the 
infant formula 
 Dose-response study 
 Lack of adequate long-term studies 
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 Lack of studies for newborns (0-1 month) 
 Lack of data on use in immunocompromised children 
 Lack of in-depth studies on the microbiology of human breast milk 
 
Answer to the questions 
The Norwegian Food Safety Authority has requested the VKM to answer the questions in two 
steps: 
 
Step 1 
1) Lactobacillus fermentum CECT5716 in infant formulae: 
a) can Lactobacillus fermentum CECT5716 safely be given to infants (from birth)? 
The species L. fermentum is included in the EFSA-list of bacteria that are presumed to be safe 
(QPS – qualified presumption of safety). The specific strain L. fermentum CECT 5716 has 
been isolated from normal human milk. It is fully susceptible to all antibiotics recommended 
by the Panel on additive and products or substances used in animal feed of EFSA and is 
considered safe regarding absence of antimicrobial resistance genes. We are not aware of any 
data indicating that this strain has been the cause of human disease.  There is therefore no 
evidence leading to consider the strain L. fermentum CECT 5716 as unsafe.  
However, there are no systematic studies where this strain has been given as a probiotic 
supplement to infant formula intended for newborns less than 1 month of age. As the effect 
and safety of probiotics are considered to be not only species- but also strain-specific, the 
adequate data for this strain used for this age-group are lacking. Thus the safety for the age 
group 0-1 months cannot be established. 
Two clinical studies conclude that the strain L. fermentum CECT 5716 is safe for healthy 
infants 1-6 months of age. 
b) are there any contraindications concerning the use of infant formulae supplemented 
with Lactobacillus fermentum CECT5716 (from birth)? 
There are no specific contraindications other than those following the above-mentioned lack 
of adequate data concerning effect and safety for this specific strain given to this age-group. 
In addition, the general considerations mentioned below (point 2) will also apply for this age-
group.   
Due to lack of data on use in immunocompromised children the use of L. fermentum CECT 
5716 in these children may be contraindicated. 
 
2) Lactobacillus fermentum CECT5716 in follow-on formulae: 
a) can Lactobacillus fermentum CECT5716 safely be given to infants (from 6 months 
age)? 
Short-term safety according to the limited number of studies provided by FBO can be 
considered acceptable. However, the long-term safety for this age group cannot be 
established. 
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b) are there any contraindications by use of follow-on formulae supplemented with 
Lactobacillus fermentum CECT5716 to infants (from 6 months age)? 
 
No specific contraindications for use of this probiotic have been mentioned in the assessed 
literature, but this aspect has apparently also not been considered as only healthy children 
have been included. Data concerning groups such as preterm children, immunocompromised 
or otherwise seriously ill children have not been included. 
However, especially for the youngest age-groups who still have an immature intestinal 
microbiota, important general questions remain concerning possible long-term effects and 
safety of probiotics remains.  
 
 
Step 2 
The term suitability should be evaluated in light of the documentation submitted by the FBO 
 
1) Is infant formulae supplemented with Lactobacillus fermentum CECT5716 suitable for 
infants (from birth)? 
 
2) Is follow-on formulae supplemented with Lactobacillus fermentum CECT5716 suitable 
for infants (from 6 months age)? 
 
As the use of the infant formulae and follow-on formulae supplemented with Lactobacillus 
fermentum CECT5716 was not assessed safe for the relevant age groups VKM concludes that 
the product is not suitable the same groups and the Panel on Nutrition, Dietetic Products, 
Novel Food and Allergy (FG7) will not assess the issue further. 
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Annex 1 
Table 1 - Long term effect of various probiotic strains on gut microbiota in infants 
Reference  
 
(Agarwal et al. 2003) 
Study design  Prospective, randomized study  
No. of subjects  
 
71 preterm infants of less than 2000 g birth weight. Infants less than 
1500 g (24 treated, 15 control) received 10(9) LGG orally twice daily 
for 21 days. 
Probiotic(s) 
strain(s) 
Lactobacillus rhamnosus GG 
Outcome 
measures  
Colonization of Lactobacillus GG(LGG) on the neonatal gut and 
modification of microbial ecology 
Results 
 
Colonization with LGG occurred in 5 of 24 (21%) infants who 
weighed less than 1500 g versus 11 of 23 (47%) in larger infants. 
Colonization was limited to infants who were not on antibiotics 
within 7 days of treatment with LGG.  
Treatment in infants weighing less than 1500 g resulted in a 
significant increase in species number by day 7, with further 
increases by day 21. This increase was mainly the result of increased 
Gram (+) and anaerobic species. No difference in species number was 
noted in controls. Mean log CFU of Gram (-) bacteria did not change 
in treated infants weighing less than 1500 g. However, Gram (+) 
mean log CFU showed a significant increase on day 21 (6.1 +/- 0.9) 
compared with day 0 (3.5 +/- 0.9) (P < 0.05). No significant changes 
in species number or quantitative counts were noted after LGG 
treatment in the infants weighing 1500 to 1999 g LGG was well 
tolerated in all infants. 
Conclusion 
 
LGG is a relatively poor colonizer in infants especially those infants 
weighing less than 1500 g at birth, it does appear to affect neonatal 
intestinal colonization patterns. 
Evaluation The divergence in results showed  that ”colonization” or ”no-
colonization” of LGG in infants gut seemed to be influenced of 
multifactorial effects in the highly complex intestinal milieu and gut 
microbiota cannot be controlled only by supplementation of probiotic 
to the milk/formula milk.   
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Reference  
 
(Chrzanowska-Liszewska et al. 2012) 
Study design  
 
Randomized study; children received probiotics or placebo within 0-
3days after birth 
No. of subjects  
 
60 patients were initially identified and enrolled but after exclusion 
criteria were applied, 21 babies were analyzed in the probiotic group 
and 26 in the placebo group.  
Probiotic(s) 
strain(s) 
 
Lactobacillus rhamnosus GG 
Outcome 
measures  
 
Presence of LGG colonization, pathogenic bacteria, somatic growth 
and length of hospital stay 
Results 
 
The number of Lactobacillus were significantly higher (p=0.014) on 
day 7, and 21 (p=0.024) in the study group, and so was the number of 
Enterobacteriaceae on all study days (p=0.004, p=0.000, p=0.000), 
and Enterococcus sp on day 21 (p=0.000). The amount of samples 
positive for staphylococci was significantly higher in the study group, 
on days 7 and 42 (p=0.001 and 0.011). We did not show a significant 
difference in weight gain upon discharge between the groups 
p=0.567, 95% CI (-168; 305) or mean of hospital stay p=0.421 95% 
CI (-13.43;5.71). 
Conclusion 
 
A preterm infant formula with an addition of probiotics leads to a 
rapid growth of LGG in the gut of bottle fed infants, but does not 
decrease the amount of pathogenic organisms, nor increase weight 
gain during enteral feeding, or decrease length of hospital stay 
Evaluation of 
the study 
The authors confirm that the number of pathogenic bacteria is higher 
in probiotic group than the control group. The reason for this finding 
has not been discussed. 
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Reference  
 
(Cox et al. 2010) 
Study design  
 
Double blind randomized. Infant feces. Given Log 9 cfu LGG per 
day, from birth to 6 month old. 
No. of subjects  Sixteen 6-month old infants 
Probiotic(s) 
strain(s) 
L. casei subsp. rhamnosus LGG 
Outcome 
measures  
DNA from feces -> PCR -> Micro array 
Results 
 
Found 1988 taxa (much more diverse than previously reported, 
method will detect as low as 0.01% of the bacterial community. Per 
individual 950 – 1333 taxa. Abundance of LGG in samples varied 
greatly, and was associated with specific increases in other 
lactobacilli and bifidobacteria (i.e. related).  
Conclusion 
 
Increased info about the way that priobitics ”work”. Caused 
”dramatic” changes in GIT microbiota (despite *). Promotion of a 
diverse probiotic flora can be key factor in protection against allergic 
disease development. 
Evaluation This is an interesting study by using molecular methods for studying 
the effects of probiotics on infants’ microbiota. However, the number 
of samples is too few to draw any firm conclusion. 
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Reference  
 
(Ismail et al. 2012) 
Study design  
 
Studied 7-day fecal samples of infants who were deemed high risk for 
allergic disease. Part of a greater study which was randomized, 
double blind, placebo-controlled. Probiotics given to mother prenatal. 
No. of subjects  
 
98 infants at high risk of allergic disease, whose mothers participated 
in a pre-natal probiotic eczema prevention study. 
Probiotic(s) 
strain(s) 
LGG as tablet/capsule 
Outcome 
measures  
 
T-RFLP analysis of 16S rRNA to assess microbial diversity of day-7 
gut microbiota. 
Results 
 
Prenatal LGG did not affect microbial diversity. (Previous study 
showed that LGG was bifidogenic). Also no influence on 
development of eczema. 
Conclusion Prenatal LGG admin does not affect postnatal flora in infants 
Evaluation Only day-7 microbiota were analysed, although the authors collected 
faecal samples on day 3, 7, 28, 90 and 180 of life. Data regarding 
changes in the infants microbiota during of the whole period, in 
particular in the late period (day 28, 90 and 180) are lacking.  
There is also lack of data regarding the mode of birth delivery; 
vaginal vs cesearen.  
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Reference  
 
(Kirjavainen et al. 2002) 
Study design  
 
This randomised study included 21 infants with early onset atopic 
eczema of whom eight were intolerant (highly sensitised group 
(HSG)) and 13 tolerant (sensitised group (SG)) to extensively 
hydrolysed whey formula (EHF). In the SG, six were weaned to EHF 
without (placebo group (PG)) and seven to EHF with Bifidobacterium 
lactis Bb-12 supplementation (bifidobacteria treated group (BbG)).  
No. of subjects  21 infants 
Probiotic(s) 
strain(s) 
Bifidobacterium lactis Bb-12 
Outcome 
measures  
 
The faecal microflora of infants in the HSG was analysed only before 
weaning whereas in the SG the faecal microflora was analysed both 
before and after weaning. 
Results 
 
Infants in the HSG had greater numbers of lactobacilli/enterococci 
than those in the SG. Serum total IgE concentration correlated 
directly with Escherichia coli counts in all infants and with 
Bacteroides counts in the HSG, indicating that the presence of these 
bacteria is associated with the extent of atopic sensitisation. The 
effect of supplementation was characterised as a decrease in the 
numbers of Escherichia coli and protection against an increase in 
Bacteroides numbers during weaning. 
Conclusion 
 
These data indicate that bifidobacterial supplementation appears to 
modify the gut microbiota in a manner that may alleviate allergic 
inflammation. Further studies are needed to confirm this conclusion. 
Evaluation of 
the study 
There were too few objects in this study to draw any firm conclusion 
and the authors have not discussed why the high number of E. coli 
should be associated the extent sensitation in infants. 
No conclusion can be taken regarding effect of probiotis on gut 
microbiota when compared with control group. 
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Reference  
 
(Klewicka et al. 2011) 
Study design  
 
Double-blind, randomized, placebo-controlled. 
No. of subjects  
 
40 children, aged 6-18 months and suffering from atopic dermatitis 
before and after 3 month. 
Probiotic(s) 
strain(s) 
Lactobacillus casei DN—114001 
Outcome 
measures  
Lactobacillus sp., Bifidobacterium, Clostridium sp. Bacteroides sp., 
Enterococcus sp. and Enterobacteriaceae. 
Results 
 
Control group: 
The total number of fecal Lactobacillus sp. decreased from 7.86 
Log10 CFU/g to 6.40 Log10 CFU/g. After the next 5 months 
(without dietary supplementation with the probiotic bacteria) the 
level of Lactobacillus sp. was maintained at the latter value.  
Probiotic group: 
During the dietary supplementation with the probiotic strain, the level 
of Bifidobacterium was maintained at 6.15-6.89 Log10 CFU/g while 
after 5 months it decreased to 5.57 Log10 CFU/g. The population of 
Clostridium sp. was reduced after 3 months of dietary 
supplementation from 6.49 to 5.83 Log10 CFU/g and was maintained 
at the latter level during the next 5 months. The dietary 
supplementation had no effect on populations of Bacteroides sp., 
Enterococcus sp. and Enterobacteriaceae. 
Conclusion 
 
Supplementation of children, with atopic dermatitis, with the 
preparation of Lactobacillus casei DN-114001 positively affected 
their gut microbiota in terms of Bifidobacteria and Clostridium 
populations. 
Evaluation of 
the study 
The number of children included in the control and test groups are 
low to conclude any firm conclusions. Furthermore, there is high 
range in bacterial cells both in control and test group. The decrease or 
increase of different bacterial species does not seem to be significant.  
It is not clear how “Lactobacillus casei DN-114001 positively 
affected their gut microbiota in terms of Bifidobacteria and 
Clostridium populations”. 
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Reference  
 
(Loo et al. 2014)  
Study design  
 
Follow-up study, analysis of the charts and electronic databases of the 
PROMPT (Probiotics in Milk for the Prevention of Atopy Trial) 
study cohort.  
No. of subjects  
 
253 infants at risk for allergy who were administered cow's milk 
supplemented with or without probiotics from the first day of life to 
the age of 6 months.  
Probiotic(s) 
strain(s) 
Different probiotic strains 
Outcome 
measures  
The cohort was followed up until the children were 5 years old and 
clinical outcomes were assessed. 
Results 
 
Of the 253 children recruited into the study, 220 (87%) completed the 
follow-up. At the age of 5 years, there were no significant differences 
between the groups in the proportion of children who had developed 
any asthma, allergic rhinitis, eczema, food allergy and sensitization to 
inhalant allergens. 
Conclusion 
 
The supplementation of probiotics in early childhood did not play a 
role in the prevention of allergic diseases. Clinical/Key Message: 
Early-life supplementation with probiotics did not change allergic 
outcomes at 5 years of age. 
Evaluation of 
the study 
No information is available regarding effect of probiotics on 
children´s microbiota.  
It seems, no matter how the probiotics may influence the gut 
microbiota, there is no effect on health. 
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Reference  
 
(Panigrahi et al. 2008)  
Study design  Randomized, double-masked, controlled trial 
No. of subjects  
 
31 infants; 19 infants in supplements and 12 in placebo group. 
 
Probiotic(s) 
strain(s) 
Lactobacillus plantarum 
Outcome 
measures  
Colonization of Lactobacillus plantarum and other bacterial species 
Results 
 
The number of bacterial species was significantly higher on days 21 
and 28 in the synbiotic preparation group compared with placebo (P = 
0.002 and 0.03, respectively). There was a linear increase in the mean 
log gram-negative colony counts in the placebo group during the 4-
week period that was significantly higher than that in the 
Lactobacillus group on days 14, 21, and 28 (P < 0.001 for each). In 
contrast, the supplement group had significantly higher gram-positive 
colony counts on days 14 (P = 0.002) and 28 (P = 0.04).  
Conclusion 
 
There was an increase in bacterial diversity and gram-positive 
organisms and a reduction of gram-negative bacterial load in the 
treatment group. 
Evaluation Infants received Lactobacillus plantarum and fructooligosaccharides 
in supplemented group or a dextrose saline placebo. Because a 
combination preparation was used, it is difficult to specifically 
attribute the colonization to either the probiotic or prebiotic 
component in this study, which is not large enough to draw any firm 
conclusion. 
The authors have not discussed the biological impact of increase in 
Gram-negative bacteria in control group and increase of Gram-
positive bacteria in supplemented group. 
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Reference  
 
(Rinne et al. 2005) 
Study design  
 
Double blind, placebo-controlled, randomized. 
Mothers received LGG 4 weeks before expected delivery. Then given 
to infants for 6 month. Breastfeeding encouraged up to 4 to 6 month. 
No. of subjects  
 
96 infants with relative with atopic dermatitis, allergic rhinitis or 
asthma. 
Probiotic(s) 
strain(s) 
LGG 
Outcome 
measures  
 
Fecal Bifidobacterium and Lactobacillus/Enterococcus counts were 
higher in breastfed than formula-fed infants at 6 months. Bacterial 
counts in feces of lactobacilli, enterococci, bifidobacteria assessed by 
FISH (Fluorescent in situ hybridisation). Also measured circulating 
Ig(G, A and M) +/- in colostrum at 3, 6 and 12 month.  
Results 
 
Levels of all Ig greater in infants given LGG. Greater bifidobacteria 
in breastfed infants (but not huge differences), effect gone by 12 
month.  
Conclusion 
 
Probiotics in mothers diet before delivery may promote maturation of 
the gut immunity. 
Evaluation The authors have not reported the effects of LGG on the composition 
of infant´s microbiota and the clinical relevance of greater Ig in 
infants given LGG has not been discussed. 
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Reference  
 
(Rinne et al. 2006) 
Study design  
 
Randomized, double blind, placebo controlled. 
The treatments of mothers/infants continued for 6 months postnatal. 
No. of subjects  
 
32 newborns whose mothers were randomized to receive placebo or 
Lactobacillus rhamnosus GG before delivery. 
Probiotic(s) 
strain(s) 
L. rhamnosus LGG 
Outcome 
measures  
Bifidobacterium, Lactobacillus/Enterococcus, Bacteroides and 
Clostridium counts in fecal samples at 6, 12, 18 and 24 months of 
age, by using fluorescent in situ hybridization (FISH).  
Results 
 
At 6 months, there were less clostridia in faeces in the placebo 
compared with the probiotic group (P = 0.026), whereas after long-
term follow-up at 2 years, there were less lactobacilli/enterococci and 
clostridia in faeces in the probiotic group than in the placebo group (P 
= 0.011 and P = 0.032, respectively). 
Conclusion Administration of LGG in the first months of life was well tolerated 
and did not significantly interfere with long-term composition or 
quantity of gut microbiota. 
Evaluation of 
the study 
The fluorescent in situ hybridization (FISH) method for the 
evaluation of the gut microbiota is not optimal. For quantitative and 
qualitative assessment of infant’s microbiota, not only fecal 
microbiota, but also microbiota in the other parts of gastrointestinal 
tract is important. Fecal samples do not give direct indication of the 
mucosal microbiota composition. Furthermore, FISH method 
recognizes only the number of bacteria is >107 per gram feces.  
There is no difference in the composition of infant microbiota in the 
test group compared to control group, neither in the short-term, nor in 
the long-term. 
 
